Final Operational Milestone #2

KA34 is an intra-articularly delivered small molecule therapeutic candidate which promotes cartilage resident mesenchymal stem cell differentiation into chondrocytes. The newly formed chondrocytes replace the dead chondrocytes, synthesize and secret extracellular matrix proteins. KA34 may generate new cartilage matrix within the pre-existing matrix without fibrotic cartilage formation. KA34 has the potential to limit the progression of osteoarthritis (OA) or reverse the OA disease process. This grant allowed California Institute for Biomedical Research to complete GLP toxicology and other IND-enabling non-clinical studies for KA34. The grant also supported GMP manufacturing of KA34 and a successful IND filing for a KA34 first-in-human clinical trial.